JP2004508339A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004508339A5 JP2004508339A5 JP2002524528A JP2002524528A JP2004508339A5 JP 2004508339 A5 JP2004508339 A5 JP 2004508339A5 JP 2002524528 A JP2002524528 A JP 2002524528A JP 2002524528 A JP2002524528 A JP 2002524528A JP 2004508339 A5 JP2004508339 A5 JP 2004508339A5
- Authority
- JP
- Japan
- Prior art keywords
- vaccine
- composition
- gene
- heat shock
- stress
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229960005486 vaccine Drugs 0.000 description 35
- 239000000203 mixture Substances 0.000 description 17
- 244000000010 microbial pathogen Species 0.000 description 16
- 238000000034 method Methods 0.000 description 15
- 108090000623 proteins and genes Proteins 0.000 description 9
- 108010004889 Heat-Shock Proteins Proteins 0.000 description 7
- 102000002812 Heat-Shock Proteins Human genes 0.000 description 6
- 230000035939 shock Effects 0.000 description 6
- 241000894006 Bacteria Species 0.000 description 4
- 239000002671 adjuvant Substances 0.000 description 4
- 238000012239 gene modification Methods 0.000 description 4
- 230000005017 genetic modification Effects 0.000 description 3
- 235000013617 genetically modified food Nutrition 0.000 description 3
- 230000002163 immunogen Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 241000194036 Lactococcus Species 0.000 description 2
- 241000607142 Salmonella Species 0.000 description 2
- 239000000427 antigen Substances 0.000 description 2
- 102000036639 antigens Human genes 0.000 description 2
- 108091007433 antigens Proteins 0.000 description 2
- 239000012634 fragment Substances 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 244000005700 microbiome Species 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000589989 Helicobacter Species 0.000 description 1
- 241000186781 Listeria Species 0.000 description 1
- 241000187747 Streptomyces Species 0.000 description 1
- 101100071650 Streptomyces coelicolor (strain ATCC BAA-471 / A3(2) / M145) hspR gene Proteins 0.000 description 1
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 1
- 241000607598 Vibrio Species 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 1
- 108091006104 gene-regulatory proteins Proteins 0.000 description 1
- 101150023890 hspR gene Proteins 0.000 description 1
- 230000028993 immune response Effects 0.000 description 1
- 230000003308 immunostimulating effect Effects 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 244000045947 parasite Species 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 229940021993 prophylactic vaccine Drugs 0.000 description 1
- 230000002685 pulmonary effect Effects 0.000 description 1
- 230000022532 regulation of transcription, DNA-dependent Effects 0.000 description 1
- 229940031439 squalene Drugs 0.000 description 1
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 1
- 229940031626 subunit vaccine Drugs 0.000 description 1
- 229960000814 tetanus toxoid Drugs 0.000 description 1
- 229940021747 therapeutic vaccine Drugs 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB0021757.0A GB0021757D0 (en) | 2000-09-04 | 2000-09-04 | Vaccine against microbial pathogens |
| PCT/GB2001/003964 WO2002020045A2 (en) | 2000-09-04 | 2001-09-04 | Vaccine against microbial pathogens |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2004508339A JP2004508339A (ja) | 2004-03-18 |
| JP2004508339A5 true JP2004508339A5 (enExample) | 2008-10-16 |
Family
ID=9898866
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2002524528A Pending JP2004508339A (ja) | 2000-09-04 | 2001-09-04 | 微生物病原体ワクチン |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20050232946A1 (enExample) |
| EP (1) | EP1315518B1 (enExample) |
| JP (1) | JP2004508339A (enExample) |
| CN (1) | CN1452495A (enExample) |
| AT (1) | ATE450270T1 (enExample) |
| AU (1) | AU2001284261A1 (enExample) |
| CA (1) | CA2421229A1 (enExample) |
| DE (1) | DE60140681D1 (enExample) |
| DK (1) | DK1315518T3 (enExample) |
| ES (1) | ES2337653T3 (enExample) |
| GB (1) | GB0021757D0 (enExample) |
| IL (1) | IL154727A0 (enExample) |
| PT (1) | PT1315518E (enExample) |
| WO (1) | WO2002020045A2 (enExample) |
| ZA (1) | ZA200301759B (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7928264B2 (en) * | 2004-09-21 | 2011-04-19 | Astellas Pharma Inc. | Aminoalcohol derivatives |
| AU2007291887B2 (en) | 2006-09-01 | 2012-09-27 | Csl Limited | Method of eliciting or inducing an immune response |
| WO2009021291A1 (en) * | 2007-08-16 | 2009-02-19 | The University Of Sydney | Mycobacterium vaccine formulation |
| US8999353B2 (en) | 2007-10-12 | 2015-04-07 | Csl Limited | Method of eliciting an immune response against pandemic influenza virus |
| GB0910591D0 (en) | 2009-06-19 | 2009-07-29 | Immunobiology Ltd | Method for the purification of protein complexes |
| GB0916557D0 (en) | 2009-09-21 | 2009-10-28 | Health Prot Agency | Commensal neisserial stress protein complexes |
| GB201104897D0 (en) | 2011-03-23 | 2011-05-04 | Immunobiology Ltd | Method for the production of protein complexes and vaccine compositions comprising the same |
| BR112013026929A2 (pt) * | 2011-04-20 | 2016-12-27 | Mico Bio Inc | composição e método para intensificação de uma resposta imune |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0506211B1 (en) * | 1986-08-18 | 1999-03-24 | British Technology Group Limited | Vaccines |
| US5776724A (en) * | 1988-10-24 | 1998-07-07 | Yale University | Chaperonin-mediated protein folding |
| JPH03204820A (ja) * | 1989-10-12 | 1991-09-06 | Nippon Saibai Suisan Kk | エビ類の細菌性疾病予防ワクチン及びその製造法 |
| JPH08509873A (ja) * | 1993-05-19 | 1996-10-22 | アンスティテュ・パストゥール | ヘリコバクター感染に対する免疫組成物、該組成物に用いられるポリペプチドおよび該ポリペプチドをコードする核酸配列 |
| US6258359B1 (en) * | 1993-05-19 | 2001-07-10 | Institut Pasteur | Immunogenic compositions against helicobacter infection, polypeptides for use in the compositions, and nucleic acid sequences encoding said polypeptides |
| JPH0748398A (ja) * | 1993-08-03 | 1995-02-21 | Nippon Oil Co Ltd | 変性蛋白質の再生方法及び変性蛋白質再生剤 |
| US6872542B1 (en) * | 1993-11-18 | 2005-03-29 | Siga Pharmaceuticals, Inc. | Treatment or prophylaxis of diseases caused by pilus-forming bacteria |
| US6420127B1 (en) * | 1994-11-18 | 2002-07-16 | Washington University | Compounds and pharmaceutical compositions for the treatment and prophylaxis of bacterial infections |
| US5961979A (en) * | 1994-03-16 | 1999-10-05 | Mount Sinai School Of Medicine Of The City University Of New York | Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens |
| WO1996040928A1 (en) * | 1995-06-07 | 1996-12-19 | Biochem Vaccines Inc. | Streptococcal heat shock proteins members of the hsp70 family |
| US5935576A (en) * | 1995-09-13 | 1999-08-10 | Fordham University | Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens |
| JP2000502054A (ja) * | 1995-11-30 | 2000-02-22 | アグリカルチャー ビクトリア サービシーズ ピーティーワイ．エルティーディー． | 治療用および診断用の組成物 |
| US6066716A (en) * | 1996-09-20 | 2000-05-23 | University Of New Mexico | Purified heat shock protein complexes |
| US5747332A (en) * | 1996-09-20 | 1998-05-05 | University Of New Mexico | Methods for purifying and synthesizing heat shock protein complexes |
| US6331388B1 (en) * | 1997-10-17 | 2001-12-18 | Wisconsin Alumni Research Foundation | Immune response enhancer |
| US5948646A (en) * | 1997-12-11 | 1999-09-07 | Fordham University | Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes |
| US6500434B1 (en) * | 1998-04-23 | 2002-12-31 | Medimmune, Inc. | Chaperone and adhesin proteins; vaccines, diagnostics and method for treating infections |
| US6248329B1 (en) * | 1998-06-01 | 2001-06-19 | Ramaswamy Chandrashekar | Parasitic helminth cuticlin nucleic acid molecules and uses thereof |
| AU770498B2 (en) * | 1998-06-19 | 2004-02-26 | Merieux Oravax | LT and CT in parenteral immunization methods against helicobacter infection |
| GB9818133D0 (en) * | 1998-08-19 | 1998-10-14 | Quadrant Holdings Cambridge | Vaccine |
| JP2002537351A (ja) * | 1999-02-22 | 2002-11-05 | ユニバーシティ・オブ・ブリティッシュ・コロンビア | コーロバクターリポ多糖免疫アジュバント |
| US7041465B1 (en) * | 1999-08-11 | 2006-05-09 | Washington University | Anti-bacterial compounds directed against pilus biogenesis, adhesion and activity; co-crystals of pilus subunits and methods of use thereof |
| GB9919734D0 (en) * | 1999-08-19 | 1999-10-20 | Colaco Camilo | Vaccines from infectious agents |
| US6677139B1 (en) * | 1999-12-23 | 2004-01-13 | Genecor International, Inc. | Methods for production of proteins in host cells |
| GB0004547D0 (en) * | 2000-02-23 | 2000-04-19 | Immunobiology Ltd | Screening method for novel vaccine candidates and compositions obtained thereby |
| AU2001257087A1 (en) * | 2000-04-17 | 2001-10-30 | Mojave Therapeutics Inc. | Heat shock protein-based antiviral vaccines |
| CN1107681C (zh) * | 2000-08-11 | 2003-05-07 | 中国科学院微生物研究所 | 乙肝病毒抗原多肽与热休克蛋白的复合物及其应用 |
| US6932985B2 (en) * | 2000-10-10 | 2005-08-23 | Auburn University | Azide method and composition for controlling deleterious organisms |
| WO2002059156A2 (en) * | 2000-12-22 | 2002-08-01 | Medimmune, Inc. | Therapeutic compounds structurally-linked to bacterial polypeptides |
| WO2003068941A2 (en) * | 2002-02-13 | 2003-08-21 | Duke University | Modulation of immune response by non-peptide binding stress response polypeptides |
| WO2003074003A2 (en) * | 2002-03-01 | 2003-09-12 | Applied Immune Technologies | Immunogens for treatment of neoplastic and infectious disease |
| CA2483925A1 (en) * | 2002-05-02 | 2004-04-29 | University Of Connecticut Health Center | Using heat shock proteins and alpha-2-macroglobulins to increase immune response to vaccines comprising heat shock protein-peptide complexes or alpha-2-macroglobulin-peptide complexes |
-
2000
- 2000-09-04 GB GBGB0021757.0A patent/GB0021757D0/en not_active Ceased
-
2001
- 2001-09-04 WO PCT/GB2001/003964 patent/WO2002020045A2/en not_active Ceased
- 2001-09-04 US US10/363,454 patent/US20050232946A1/en not_active Abandoned
- 2001-09-04 ES ES01963230T patent/ES2337653T3/es not_active Expired - Lifetime
- 2001-09-04 PT PT01963230T patent/PT1315518E/pt unknown
- 2001-09-04 EP EP01963230A patent/EP1315518B1/en not_active Expired - Lifetime
- 2001-09-04 CA CA002421229A patent/CA2421229A1/en not_active Abandoned
- 2001-09-04 AT AT01963230T patent/ATE450270T1/de active
- 2001-09-04 DK DK01963230.6T patent/DK1315518T3/da active
- 2001-09-04 CN CN01815133A patent/CN1452495A/zh active Pending
- 2001-09-04 JP JP2002524528A patent/JP2004508339A/ja active Pending
- 2001-09-04 AU AU2001284261A patent/AU2001284261A1/en not_active Abandoned
- 2001-09-04 DE DE60140681T patent/DE60140681D1/de not_active Expired - Lifetime
- 2001-09-04 IL IL15472701A patent/IL154727A0/xx unknown
-
2003
- 2003-03-03 ZA ZA200301759A patent/ZA200301759B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Yadav et al. | Vaccines: present status and applications | |
| Jorge et al. | The development of veterinary vaccines: a review of traditional methods and modern biotechnology approaches | |
| Levine et al. | Vaccine development strategies for improving immunization: the role of modern immunology | |
| Strugnell et al. | Vaccine antigens | |
| Tahamtan et al. | An overview of history, evolution, and manufacturing of various generations of vaccines | |
| JP5651677B2 (ja) | 各種血清型のブタ連鎖球菌（Ｓｔｒｅｐｔｏｃｏｃｃｕｓｓｕｉｓ）細菌から防御するためのワクチン | |
| Boutier et al. | Current knowledge and future prospects of vaccines against cyprinid herpesvirus 3 (CyHV-3) | |
| JP2004536106A5 (enExample) | ||
| Bonanni et al. | Vaccine evolution | |
| JP2004508339A5 (enExample) | ||
| CN101914564B (zh) | 一种大肠杆菌多个肠毒素基因的融合体及其应用 | |
| JP2004508339A (ja) | 微生物病原体ワクチン | |
| CA2382336C (en) | Vaccines from infectious agents | |
| Wan et al. | Immunogenic analysis of two DNA vaccines of avian reovirus mediated by attenuated Salmonella typhimurium in chickens | |
| Kumar et al. | Whole-cell vaccine preparation: Options and perspectives | |
| Jivani et al. | veterinary vaccines: past, present and future–a review | |
| Navruzshoeva et al. | Current trends in increasing the biological activity of vaccine strains of Bacillus anthracic | |
| Božić et al. | An overview of current vacccines for the prophylaxis of bacterical infections Pres | |
| Gupta et al. | Role of Microbes in Production of Vaccines | |
| Lina | Efficiency Evaluation of 5BT, a Genetically Recombinant Multi-epitope-protein, for Its Application as a Subunit Vaccine against Foot and Mouth Disease | |
| Vasudevan | Biotechnological Innovation for Sustainable Immunization | |
| KHATRI | Therapeutic DNA Vaccines:“Future strategies” | |
| Ellis | New technologies for bacterial vaccines | |
| Parnham | opments in vaccinology will be outlined. | |
| Massabni et al. | Biotechnology and vaccines |